Analysis of graft survival in a trial of stem cell transplant in ALS
dc.contributor.author | Tadesse, Tezeta | en_US |
dc.contributor.author | Gearing, Marla | en_US |
dc.contributor.author | Senitzer, David | en_US |
dc.contributor.author | Saxe, Debra | en_US |
dc.contributor.author | Brat, Daniel J. | en_US |
dc.contributor.author | Bray, Robert | en_US |
dc.contributor.author | Gebel, Howard | en_US |
dc.contributor.author | Hill, Charles | en_US |
dc.contributor.author | Boulis, Nicholas | en_US |
dc.contributor.author | Riley, Jonathan | en_US |
dc.contributor.author | Feldman, Eva | en_US |
dc.contributor.author | Johe, Karl | en_US |
dc.contributor.author | Hazel, Thomas | en_US |
dc.contributor.author | Polak, Meraida | en_US |
dc.contributor.author | Bordeau, Jane | en_US |
dc.contributor.author | Federici, Thais | en_US |
dc.contributor.author | Glass, Jonathan D. | en_US |
dc.date.accessioned | 2014-12-09T16:53:42Z | |
dc.date.available | WITHHELD_12_MONTHS | en_US |
dc.date.available | 2014-12-09T16:53:42Z | |
dc.date.issued | 2014-11 | en_US |
dc.identifier.citation | Tadesse, Tezeta; Gearing, Marla; Senitzer, David; Saxe, Debra; Brat, Daniel J.; Bray, Robert; Gebel, Howard; Hill, Charles; Boulis, Nicholas; Riley, Jonathan; Feldman, Eva; Johe, Karl; Hazel, Thomas; Polak, Meraida; Bordeau, Jane; Federici, Thais; Glass, Jonathan D. (2014). "Analysis of graft survival in a trial of stem cell transplant in ALS." Annals of Clinical and Translational Neurology 1(11): 900-908. | en_US |
dc.identifier.issn | 2328-9503 | en_US |
dc.identifier.issn | 2328-9503 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/109593 | |
dc.description.abstract | Objective The first US Food and Drug Administration–approved clinical trial to treat amyotrophic lateral sclerosis ( ALS ) with neural stem cell–based therapy is in progress. The goal of the current study was to identify and assess the survival of human spinal cord–derived neural stem cells ( HSSC s) transplanted into the spinal cord in patients with ALS . Methods Spinal cords transplanted with HSSCs were examined from six autopsy cases. Homogenized tissues were interrogated for the presence of donor versus recipient DNA using real‐time PCR methods ( qPCR ). Fluorescence in situ hybridization (FISH) was performed using DNA probes for XY chromosomes to identify male donor HSSCs in one female case, and immunohistochemistry (IHC) was used to characterize the identified donor cells. Results Genomic DNA from donor HSSC s was identified in all cases, comprising 0.67–5.4% of total tissue DNA in patients surviving 196 to 921 days after transplantation. In the one female patient a “nest” of cells identified on H&E staining were XY ‐positive by FISH , confirming donor origin. A subset of XY ‐positive cells labeled for the neuronal marker NeuN and stem cell marker SOX 2. Interpretation This is the first study to identify human neural stem cells transplanted into a human spinal cord. Transplanted HSSC s survived up to 2.5 years posttransplant. Some cells differentiated into neurons, while others maintained their stem cell phenotype. This work is a proof of concept of the survival and differentiation of human stems cell transplanted into the spinal cord of ALS patients. | en_US |
dc.publisher | Wiley Periodicals, Inc. | en_US |
dc.title | Analysis of graft survival in a trial of stem cell transplant in ALS | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Neurology and Neurosciences | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/109593/1/acn3134.pdf | |
dc.identifier.doi | 10.1002/acn3.134 | en_US |
dc.identifier.source | Annals of Clinical and Translational Neurology | en_US |
dc.identifier.citedreference | Faravelli I, Riboldi G, Nizzardo M, et al. Stem cell transplantation for amyotrophic lateral sclerosis: therapeutic potential and perspectives on clinical translation. Cell Mol Life Sci 2014; 71: 3257 – 3268. | en_US |
dc.identifier.citedreference | Guo X, Johe K, Molnar P, et al. Characterization of a human fetal spinal cord stem cell line, NSI‐566RSC, and its induction to functional motoneurons. J Tissue Eng Regen Med 2010; 4: 181 – 193. | en_US |
dc.identifier.citedreference | Xu L, Ryugo DK, Pongstaporn T, et al. Human neural stem cell grafts in the spinal cord of SOD1 transgenic rats: differentiation and structural integration into the segmental motor circuitry. J Comp Neurol 2009; 514: 297 – 309. | en_US |
dc.identifier.citedreference | Yan J, Xu L, Welsh AM, et al. Extensive neuronal differentiation of human neural stem cell grafts in adult rat spinal cord. PLoS Med 2007; 4: e39. | en_US |
dc.identifier.citedreference | Xu L, Yan J, Chen D, et al. Human neural stem cell grafts ameliorate motor neuron disease in SOD‐1 transgenic rats. Transplantation 2006; 82: 865 – 875. | en_US |
dc.identifier.citedreference | Mazzini L, Mareschi K, Ferrero I, et al. Mesenchymal stromal cell transplantation in amyotrophic lateral sclerosis: a long‐term safety study. Cytotherapy 2012; 14: 56 – 60. | en_US |
dc.identifier.citedreference | Mackay‐Sim A, Feron F, Cochrane J, et al. Autologous olfactory ensheathing cell transplantation in human paraplegia: a 3‐year clinical trial. Brain 2008; 131 ( Pt 9 ): 2376 – 2386. | en_US |
dc.identifier.citedreference | Deda H, Inci MC, Kurekci AE, et al. Treatment of amyotrophic lateral sclerosis patients by autologous bone marrow‐derived hematopoietic stem cell transplantation: a 1‐year follow‐up. Cytotherapy 2009; 11: 18 – 25. | en_US |
dc.identifier.citedreference | Martinez‐Morales PL, Revilla A, Ocana I, et al. Progress in stem cell therapy for major human neurological disorders. Stem Cell Rev 2013; 9: 685 – 699. | en_US |
dc.identifier.citedreference | Thomsen GM, Gowing G, Svendsen S, Svendsen CN. The past, present and future of stem cell clinical trials for ALS. Exp Neurol 2014; In Press, Corrected Proof, Available online 6 March 2014. | en_US |
dc.identifier.citedreference | Blanquer M, Moraleda JM, Iniesta F, et al. Neurotrophic bone marrow cellular nests prevent spinal motoneuron degeneration in amyotrophic lateral sclerosis patients: a pilot safety study. Stem Cells 2012; 30: 1277 – 1285. | en_US |
dc.identifier.citedreference | Boulis NM, Federici T, Glass JD, et al. Translational stem cell therapy for amyotrophic lateral sclerosis. Nat Rev Neurol 2011; 8: 172 – 176. | en_US |
dc.identifier.citedreference | Feldman EL, Boulis NM, Hur J, et al. Intraspinal neural stem cell transplantation in amyotrophic lateral sclerosis: phase 1 trial outcomes. Ann Neurol 2014; 75: 363 – 373. | en_US |
dc.identifier.citedreference | Riley J, Federici T, Polak M, et al. Intraspinal stem cell transplantation in amyotrophic lateral sclerosis: a phase I safety trial, technical note, and lumbar safety outcomes. Neurosurgery 2012; 71: 405 – 416; discussion 16. | en_US |
dc.identifier.citedreference | Glass JD, Boulis NM, Johe K, et al. Lumbar intraspinal injection of neural stem cells in patients with amyotrophic lateral sclerosis: results of a phase I trial in 12 patients. Stem Cells 2012; 30: 1144 – 1151. | en_US |
dc.identifier.citedreference | Appel SH, Engelhardt JI, Henkel JS, et al. Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosis. Neurology 2008; 71: 1326 – 1334. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.